NAD+ Nasal Spray: What the Evidence Actually Shows

NAD+ nasal spray is sold as the convenient version of the NAD+ drip: no needle, no clinic chair, no three-hour infusion. Six of the providers ranked on this site sell one, and the marketing around it is about energy, focus, and aging.

There is exactly one published study of NAD+ given by that route. It used cultured cells and mice, and what it measured was the recovery of smell.

That gap — between the route people are buying and the route anyone has studied — is the whole story here, and none of the pages currently ranking for this product will tell you about it, because all of them sell it.

What has actually been studied

The one study is Yoo and colleagues, published in Experimental & Molecular Medicine in 2026, titled "Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction"¹. Its own abstract states the design plainly: cultured human olfactory stem cells were treated with NAD, and then, in the words of the paper, "mice with ZnSO4-induced anosmia were treated with i.n. NAD, intraperitoneal dexamethasone, or PBS."

Read that carefully, because it is the entire human-relevant evidence base for this route:

• •The subjects were cells in a dish and mice, not people.
• •The model was chemically induced smell loss — anosmia caused by zinc sulfate — not fatigue, not brain fog, not aging.
• •The endpoint was restoring olfactory function, which is not what any provider markets a nasal spray for.

This is not a criticism of the study. It is a perfectly reasonable piece of preclinical research into a specific problem. It simply is not evidence that spraying NAD+ up your nose does anything for the reasons it is sold.

What the wider NAD+ record says about routes

The nasal spray does not exist in isolation — it is one of several ways NAD+ is sold, and the broader record for the non-oral routes is thin in a specific, documented way.

A 2026 PRISMA-guided systematic review screened 113 eligible studies, 33 of them human, and reported in its own results text that "no eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications"². That review covered compounds given orally or parenterally. The injectable route — the one with far more money and clinic time behind it than the nasal spray — has no eligible outcome trials either.

The single human pharmacokinetic study of infused NAD+ reported that during a six-hour infusion, "no change in plasma [NAD+] or metabolites... were observed until after 2 h"³. Two independent 2026 reviews concluded that intravenous NAD+ should be treated as experimental rather than evidence-based⁴⁵.

If the intravenous route — the most studied of the non-oral options — has no outcome trials, a nasal spray with one preclinical mouse paper behind it is not in a stronger position. It is in a weaker one.

The absorption question nobody has answered for this route

There is a specific reason the nasal route is worth its own scrutiny rather than being treated as "injection, but easier."

NAD+ is a large, charged molecule. The entire argument for injecting it is that swallowing it does not work — the molecule is broken down before it reaches circulation. A nasal spray is proposed as a middle path: absorption across the nasal mucosa, bypassing the gut.

No published human pharmacokinetic study establishes that this happens. The infusion study above struggled to demonstrate a prompt rise in plasma NAD+ even when the compound was delivered directly into a vein³. Whether a spray into the nose achieves anything measurable in blood or brain has not been shown in people.

That is the unanswered question underneath every nasal-spray product page: not "does NAD+ matter" — it plainly does, biologically⁶ — but "does spraying it into your nose put any meaningful amount anywhere useful."

What six providers actually charge

This is where an independent page can say something the sellers cannot: what the market actually looks like.

Six providers ranked on this site sold a compounded NAD+ nasal spray when their prices were last read, in August 2026, and the spread was wide — roughly $112 to $179 a month, a difference of about 60% between the cheapest and the dearest for the same class of product. Two of those figures are floors rather than flat rates, one is reachable only on the provider's longest plan, and one is discounted if you prepay a quarter.

Those conditions matter more than the headline numbers, and they change. Our NAD+ provider comparison carries the current figure for each, what each one's price actually includes, and which providers name the pharmacy that compounds it — the last of which is worth more than the price difference, given the product's evidence base.

What this means if you are considering one

The honest summary is short:

• •The only published research on NAD+ by this route is preclinical, and it studied smell recovery in mice.
• •The better-funded injectable route has no eligible outcome trials in a 2026 systematic review of the field.
• •Nobody has shown, in people, that an intranasal dose reaches anywhere it would need to reach.
• •It is nonetheless sold by six providers we track, at a spread of about 60%.

None of that means NAD+ is not important biology, or that the spray is unsafe. It means the specific claim being sold — that this delivery route does something useful for energy or aging — has not been tested in humans, and the price you pay is not tracking evidence, because there is not enough evidence for it to track.

For the wider picture, our NAD+ evidence review covers the injectable and IV literature in full, NAD+ dosage and side effects covers what the dosing studies actually administered, and NMN vs NAD+ covers how the oral precursor route compares.